Across TCGA pan-cancer cohorts, MIR4670 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of MIR4670’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where MIR4670 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR4670 is over-expressed in tumor.
STAD are the cancer types where MIR4670 tumor–normal differential expression is most reproducible.